We are beginning by performing research on the variation found in CBT (cannabinoid based therapeutics).   Frighteningly, we know more about the rabbit, cow and rice genomes then we do about the cannabis genome.  Genomic sequencing has evolved greatly in the last decade.  It is now possible using next-generation Sequencing protocols to sequence an entire genome in a matter of days.  Utilizing next-generation sequencing, Verda Bio is building a database of genomic variation found in CBTs.  We know that medical cannabis patients report variation between medicinal products. Chemical analysis of cannabis strains has shown huge variation in cannabinoid profiles of cannabis strains labeled with the same strain name.

Update:  Verda Bio has completed whole genome genetic analysis of multiple samples.   Contact us to discuss analysis of your sample, or for access to our data.

By preforming DNA sequencing on a variety of cannabis .plants and comparing the DNA and chemical profiles of strains, we will be able to better understand the variation reported by patients and laboratory testing and begin to control for these differences to create a consistent medical product.  Researchers can not run clinical trials on strains due to variability.  Physicians can not confidently advise patients on the best medical cannabis products for them due to lack of clinical data.  Leaving patients with no idea which products are safe and effective.

Cannabinoids: Cannabis is composed of over 85 cannabinoids.

These cannabinoids have been shown to modulate neurotransmission, modulate the endocannabinoid system, reduce inflammation, control ion-channels, induce apoptosis of cancer cells, inhibit angiogenesis, regulate cell cycle genes and affect oxidative stress.  The cannabinoids activate cannabinoid receptors (CB1 & CB2) in the body.  The CB1 receptor is primarily located in the brain, but also found in other regions such as the reproductive system.  The CB2 receptor is found in the immune system, peripheral nervous system and several other organs.  Different cannabinoids have different affinity profiles for the CB1 versus the CB2 receptor.  Further compounding the issue, cannabinoids are reported to have synergistic relationships. This is one of the hypothesized reasons for why patients report negative clinical outcomes for the prescription marinol (synthetic THC); alone THC does not confer the same clinical results as it does when in combination with other cannabinoids.

Disease vs. Strain: Different disease may require different cannabinoids receptor activation events.  We can not expect a single strain of cannabis to work for every disease.   You would not expect an antibiotic to kill bacteria and eliminate joint pain.  By understanding the source of the cannabinoid variation and mechanism of action, we can begin to tailor medicinal cannabis to better meet the needs of patients.  We can make clinical products that have been clinically validated.  Researchers, physicians and patients need access to standardized cannabis strains.

Click here to read about our analytical research.